PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.98%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-10.41%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-26.33%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-26.33%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-12.97%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-12.50%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.35%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
38.54%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
78.76%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-2.53%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
16.81%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
63.75%
3Y revenue/share CAGR similar to AVGO's 60.90%. Walter Schloss would assume both companies experience comparable short-term cycles.
160.39%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
34.06%
Below 50% of AVGO's 73.80%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
55.27%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
124.14%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
7.41%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
492.03%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
269.66%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
41.08%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
2.06%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
64.52%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
29.35%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
13.43%
Below 50% of AVGO's 38.29%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-13.69%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-7.37%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.00%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.65%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-1.04%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.04%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.72%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.